Data Year:

For its 2024 fiscal year, VIR BIOTECHNOLOGY INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Ann (Aine) Hanly Ph.D.
Executive Vice President and Chief Technology Officer
Total Compensation $1,395,162 View details Pay Rank By Title In Biotechnology industry #18 View more
Sung Lee
Former Executive Vice President and Chief Financial Officer
Total Compensation $1,739,557 View details Pay Rank By Title In Biotechnology industry #264 View more
Marianne De Backer M.Sc., Ph.D., MBA
Chief Executive Officer and Director
Total Compensation $9,255,903 View details Pay Rank By Title In Biotechnology industry #118 View more
Vanina de Verneuil J.D.
Executive Vice President, General Counsel and Corporate Secretary
Total Compensation $1,669,471 View details Pay Rank By Title In Biotechnology industry #56 View more
Jason O'Byrne MBA
Executive Vice President and Chief Financial Officer
Total Compensation $1,919,827 View details Pay Rank By Title In Biotechnology industry #243 View more
Mark Eisner M.D., M.P.H.
Executive Vice President and Chief Medical Officer
Total Compensation $2,756,265 View details Pay Rank By Title In Biotechnology industry #88 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at VIR BIOTECHNOLOGY INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. VIR BIOTECHNOLOGY INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. VIR BIOTECHNOLOGY INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Ann (Aine) Hanly Ph.D.
Executive Vice President and Chief Technology Officer
Total Cash $512,367 Equity $829,595 Other $53,200 $1,395,162
Sung Lee
Former Executive Vice President and Chief Financial Officer
Total Cash $684,527 Equity $1,021,040 Other $33,990 $1,739,557
Marianne De Backer M.Sc., Ph.D., MBA
Chief Executive Officer and Director
Total Cash $4,442,033 Equity $4,467,050 Other $346,820 $9,255,903
Vanina de Verneuil J.D.
Executive Vice President, General Counsel and Corporate Secretary
Total Cash $1,083,019 Equity $574,335 Other $12,117 $1,669,471
Jason O'Byrne MBA
Executive Vice President and Chief Financial Officer
Total Cash $280,492 Equity $1,639,335 Other $0 $1,919,827
Mark Eisner M.D., M.P.H.
Executive Vice President and Chief Medical Officer
Total Cash $975,297 Equity $1,777,845 Other $3,123 $2,756,265
For its 2024 fiscal year, VIR BIOTECHNOLOGY INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Marianne De Backer M.Sc., Ph.D., MBA CEO Pay $9,255,903 Median Employee Pay $328,725 CEO Pay Ratio 28:1
For its 2024 fiscal year, VIR BIOTECHNOLOGY INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Elliott Sigal, M.D., Ph.D. Total Cash $280,583
George Scangos, Ph.D. Total Cash $269,333
Janet Napolitano, J.D. Total Cash $270,583
Jeffrey S. Hatfield Total Cash $279,474
Norbert Bischofberger, Ph.D. Total Cash $445,136
Phillip Sharp, Ph.D. Total Cash $26,607
Ramy Farid, Ph.D. Total Cash $446,336
Robert More Total Cash $283,083
Robert Nelsen Total Cash $263,083
Robert Perez Total Cash $24,560
Saira Ramasastry Total Cash $285,926
Vicki Sato, Ph.D. Total Cash $295,583
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.